Search Results 231-240 of 16605 for mesenteric fat and ibd

1. Small Bowel Microbiota Characterization in Healthy Individuals Before and After Consumption of a Western Diet - Mayo Clinic

   < or = 13% of daily calories from saturated fat. Exclusion Criteria: Patients who do not meet the above diet requirements. Known diagnosis of inflammatory ...

2. Obesity - Symptoms and causes - Mayo Clinic

   Obesity is a complex disease involving having too much body fat. Obesity isn't just a cosmetic concern. It's a medical problem that increases the risk of ...

3. Developing Novel Microbiota-Targeted Therapies for Irritable Bowel Syndrome - Mayo Clinic

   This longitudinal study is being done to understand mechanisms underlying development of irritable bowel syndrome (IBS) and the role of the gut bacteria in ...

4. Crohn's disease - Doctors and departments - Mayo Clinic

   Departments that treat this condition · Colon and Rectal Surgery · Gastroenterology and Hepatology · Inflammatory Bowel Disease Clinic · Laboratory Medicine and ...

5. Assessing the Utility of Quantitative Fecal Fat Studies to Diagnose Small Intestinal Bacterial Overgrowth (SIBO) - Mayo Clinic

   The purpose of this study is to understand how the results from a fecal fat test compare to results from the duodenal aspirate culture which was collected ...

6. 7 signs and symptoms not to ignore - Mayo Clinic

   1. Unexplained weight loss · 2. Persistent or high fever · 3. Shortness of breath · 4. Unexplained changes in bowel habits · 5. Confusion or personality changes · 6.

7. Long-Term Safety of PF-00547659 in Ulcerative Colitis - Mayo Clinic

   Subjects with Ulcerative Colitis who have completed an induction study with PF-00547659 will receive an additional 72 weeks of open-label treatment to ...

8. Study of the Research Medicine CIN-103 in Adults With Irritable Bowel Syndrome With Predominant Diarrhea (IBS-D). - Mayo Clinic

   The purpose of this study is to evaluate if the study drug, CIN-103, can help reduce the symptoms associated with irritable bowel syndrome with predominant ...

9. Understanding the role of proteolytic activity in mediating irritable bowel syndrome symptoms and disruption of intestinal barrier function - Mayo Clinic

   Mayo Clinic researchers examined fecal proteolytic activity in individuals with post-infection and constipation-predominant irritable bowel syndrome, ...

10. A Study to Collect Biospecimens (Blood, Stool and Intestinal Biopsies) to Support the Development of Specific Biomarkers of Treatment Response to Infliximab and Vedolizumab in Children with IBD - Mayo Clinic

    ... intestinal biopsies) to support the development of specific biomarkers of treatment response to infliximab and vedolizumab in children with IBD.